Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies. However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour anti...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.954235/full |
| _version_ | 1811188372352270336 |
|---|---|
| author | Xinyi Xiao Yazhuo Wang Zhengbang Zou Yufei Yang Xinyu Wang Xin Xin Sanfang Tu Yuhua Li Yuhua Li |
| author_facet | Xinyi Xiao Yazhuo Wang Zhengbang Zou Yufei Yang Xinyu Wang Xin Xin Sanfang Tu Yuhua Li Yuhua Li |
| author_sort | Xinyi Xiao |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies. However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour antigens, intrinsic resistance of tumours to death signalling, and immune suppressive microenvironment. Rational combined modality treatments are regarded as a promising strategy to further unlock the antitumor potential of CAR T cell therapy, which can be applied before CAR T cell infusion as a conditioning regimen or in ex vivo culture settings as well as concomitant with or after CAR T cell infusion. In this review, we summarize the combinatorial strategies, including chemotherapy, radiotherapy, haematopoietic stem cell transplantation, targeted therapies and other immunotherapies, in an effort to further enhance the effectiveness of this impressive therapy and benefit more patients. |
| first_indexed | 2024-04-11T14:19:20Z |
| format | Article |
| id | doaj.art-ab7f4ff6db574dc68951002776d30a04 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T14:19:20Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-ab7f4ff6db574dc68951002776d30a042022-12-22T04:19:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.954235954235Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignanciesXinyi Xiao0Yazhuo Wang1Zhengbang Zou2Yufei Yang3Xinyu Wang4Xin Xin5Sanfang Tu6Yuhua Li7Yuhua Li8The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaSchool of Rehabilitation Sciences, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaBioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, ChinaChimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies. However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour antigens, intrinsic resistance of tumours to death signalling, and immune suppressive microenvironment. Rational combined modality treatments are regarded as a promising strategy to further unlock the antitumor potential of CAR T cell therapy, which can be applied before CAR T cell infusion as a conditioning regimen or in ex vivo culture settings as well as concomitant with or after CAR T cell infusion. In this review, we summarize the combinatorial strategies, including chemotherapy, radiotherapy, haematopoietic stem cell transplantation, targeted therapies and other immunotherapies, in an effort to further enhance the effectiveness of this impressive therapy and benefit more patients.https://www.frontiersin.org/articles/10.3389/fimmu.2022.954235/fullCAR T cellresistancerelapsecombination therapychemotherapyradiotherapy |
| spellingShingle | Xinyi Xiao Yazhuo Wang Zhengbang Zou Yufei Yang Xinyu Wang Xin Xin Sanfang Tu Yuhua Li Yuhua Li Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies Frontiers in Immunology CAR T cell resistance relapse combination therapy chemotherapy radiotherapy |
| title | Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies |
| title_full | Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies |
| title_fullStr | Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies |
| title_full_unstemmed | Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies |
| title_short | Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies |
| title_sort | combination strategies to optimize the efficacy of chimeric antigen receptor t cell therapy in haematological malignancies |
| topic | CAR T cell resistance relapse combination therapy chemotherapy radiotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.954235/full |
| work_keys_str_mv | AT xinyixiao combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT yazhuowang combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT zhengbangzou combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT yufeiyang combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT xinyuwang combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT xinxin combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT sanfangtu combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT yuhuali combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies AT yuhuali combinationstrategiestooptimizetheefficacyofchimericantigenreceptortcelltherapyinhaematologicalmalignancies |